Trials / Unknown
UnknownNCT00090714
To Find the Best Dose of pVGI.1(VEGF2) to Benefit Angina Patients When Given With an Experimental Injection Catheter
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 404 (planned)
- Sponsor
- Corautus Genetics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the optimum effective dose of recombinant plasmid DNA \[pVGI.1(VEGF2)\] gene therapy administered using an experimental cardiac direct injection catheter (Stiletto™) system needed to benefit patients with severe Angina Pectoris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | pVGI.1(VEGF2) |
Timeline
- Start date
- 2004-08-01
- First posted
- 2004-09-06
- Last updated
- 2006-04-20
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00090714. Inclusion in this directory is not an endorsement.